412 related articles for article (PubMed ID: 32342347)
21. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
[TBL] [Abstract][Full Text] [Related]
22. Effect of Radioactive Iodine Therapy on Cancer-Specific Survival of Papillary Thyroid Cancer Tall Cell Variant.
Dai P; Zhao W; Zheng X; Luo H; Wang X
J Clin Endocrinol Metab; 2024 Feb; 109(3):e1260-e1266. PubMed ID: 37804527
[TBL] [Abstract][Full Text] [Related]
23. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.
Sacks W; Wong RM; Bresee C; Braunstein GD
Thyroid; 2015 Apr; 25(4):377-85. PubMed ID: 25578116
[TBL] [Abstract][Full Text] [Related]
24. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
[TBL] [Abstract][Full Text] [Related]
25. High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?
Wei L; Bai L; Zhao L; Yu T; Ma Q; Ji B
World J Surg; 2019 May; 43(5):1256-1263. PubMed ID: 30684002
[TBL] [Abstract][Full Text] [Related]
26. Intermediate-Risk Papillary Thyroid Cancer: Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy.
Llamas-Olier AE; Cuéllar DI; Buitrago G
Thyroid; 2018 Oct; 28(10):1311-1317. PubMed ID: 30105948
[TBL] [Abstract][Full Text] [Related]
27. Assessment of the prognostic value of the 8th AJCC staging system for patients with clinically staged prostate cancer; A time to sub-classify stage IV?
Abdel-Rahman O
PLoS One; 2017; 12(11):e0188450. PubMed ID: 29182656
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the 8th AJCC staging system for pathologically versus clinically staged pancreatic adenocarcinoma: A time to revisit a dogma?
Abdel-Rahman O
Hepatobiliary Pancreat Dis Int; 2018 Feb; 17(1):64-69. PubMed ID: 29428107
[TBL] [Abstract][Full Text] [Related]
29. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma.
Suman P; Wang CH; Moo-Young TA; Prinz RA; Winchester DJ
Am Surg; 2016 Sep; 82(9):807-14. PubMed ID: 27670568
[TBL] [Abstract][Full Text] [Related]
30. Radioactive iodine in low- to intermediate-risk papillary thyroid cancer.
Zhao H; Gong Y
Front Endocrinol (Lausanne); 2022; 13():960682. PubMed ID: 36034423
[TBL] [Abstract][Full Text] [Related]
31. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.
Sohn SY; Choi JY; Jang HW; Kim HJ; Jin SM; Kim SW; Suh S; Hur KY; Kim JH; Chung JH; Kim SW
Thyroid; 2013 Jun; 23(6):741-7. PubMed ID: 23205883
[TBL] [Abstract][Full Text] [Related]
32. Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma.
Kim Y; Roh JL; Song D; Cho KJ; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2020 Oct; 122(5):906-913. PubMed ID: 32588461
[TBL] [Abstract][Full Text] [Related]
33. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope.
Podnos YD; Smith DD; Wagman LD; Ellenhorn JD
J Surg Oncol; 2007 Jul; 96(1):3-7. PubMed ID: 17567872
[TBL] [Abstract][Full Text] [Related]
34. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
[TBL] [Abstract][Full Text] [Related]
35. The Updated AJCC/TNM Staging System for Papillary Thyroid Cancer (8th Edition): From the Perspective of Genomic Analysis.
Kim K; Kim JH; Park IS; Rho YS; Kwon GH; Lee DJ
World J Surg; 2018 Nov; 42(11):3624-3631. PubMed ID: 29750323
[TBL] [Abstract][Full Text] [Related]
36. Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition.
Chow SM; Yau S; Kwan CK; Poon PC; Law SC
Endocr Relat Cancer; 2006 Dec; 13(4):1159-72. PubMed ID: 17158761
[TBL] [Abstract][Full Text] [Related]
37. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
[TBL] [Abstract][Full Text] [Related]
38. TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.
Suman P; Wang CH; Abadin SS; Block R; Raghavan V; Moo-Young TA; Prinz RA; Winchester DJ
Endocr Pract; 2016 Jul; 22(7):822-31. PubMed ID: 27018620
[TBL] [Abstract][Full Text] [Related]
39. Radioactive iodine in differentiated thyroid cancer: a national database perspective.
Orosco RK; Hussain T; Noel JE; Chang DC; Dosiou C; Mittra E; Divi V; Orloff LA
Endocr Relat Cancer; 2019 Oct; 26(10):795-802. PubMed ID: 31443087
[TBL] [Abstract][Full Text] [Related]
40. Utility of Early Postoperative Unstimulated Thyroglobulin in Influencing Decision Making in Patients with Papillary Thyroid Carcinoma.
McDow AD; Shumway CM; Pitt SC; Schneider DF; Sippel RS; Long KL
Ann Surg Oncol; 2019 Nov; 26(12):4002-4007. PubMed ID: 31267301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
